AHR levels in tumors predict response to Keytruda and other anti-PD-1 therapies in NSCLC

TECHNOLOGY: Tissue markers

Tumor levels of AHR could help predict response to Keytruda pembrolizumab and other PD-1 inhibitors in NSCLC. In 37 patients treated with Keytruda, high tumor levels of AHR protein were associated with response to Keytruda. Next steps include validating the association between AHR expression levels and clinical outcomes in patients treated with Keytruda and other PD-1/PD-L1 inhibitors...